Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 in a Prostatectomy Model
NCT07054346Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Apr 2027
- Modality
- Alpha Emitters, Beta Emitters, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan and actinium-225 PSMA-617 in prostate cancer (PCa) (3 arms). Primary endpoints: Mean of tumor absorbed dose at 1 week and Rate of Cluster of differentiation 3 positive (CD3+) T cell infiltration. Started Jul 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetanactinium-225 PSMA-617
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07054346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054346.